Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-05-22 14:17:51 UTC |
---|
Update Date | 2022-03-07 02:49:15 UTC |
---|
HMDB ID | HMDB0002387 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Beryllium |
---|
Description | Beryllium is a light-weight metallic element, which was first recognized as a lung hazard in Europe in the 1930s, shortly after its first production in modern industry. People exposed to beryllium compounds are at increased risk of developing beryllium sensitization and chronic beryllium disease (CBD). The chronic lung disease was first described among workers exposed to beryllium-containing materials used in the manufacture of fluorescent lamps. In primary production of beryllium metal, which was used in nuclear weapons components, physicians recognized severe dermatitis, reversible pneumonitis, and chronic granulomatous lung disease. Physiologically, this metal/element exists as an ion in the body. It is now recognized that the physicochemical properties of beryllium compounds may account for the differing clinical presentations in different industries. In primary production of beryllium metal, soluble salts are present and cause rashes in approximately one fourth of exposed workers and reversible acute pneumonitis in a smaller portion of the workforce. After heavy inhalation exposures, radiographic abnormalities evolve at approximately three weeks; resolution of symptoms and radiologic abnormalities away from exposure occur only after months, but symptoms recur immediately upon reexposure. The granulomatous nature of chronic beryllium disease is now known to be caused by cell-mediated sensitization to beryllium. Chronic beryllium disease (CBD) is a granulomatous lung disorder characterized by the accumulation of beryllium-specific CD4(+) T cells. Depending on genetic susceptibility and the nature of the exposure, CBD occurs in up to 20% of exposed workers. Genetic susceptibility has been associated with particular HLA-DP alleles, especially those possessing a negatively charged glutamic acid residue at the 69th position of the beta-chain. The mechanism for this association lies in the ability of these HLA-DP molecules to bind and present beryllium to pathogenic CD4(+) T cells. Large numbers of effector memory, beryllium-specific CD4(+) T cells are recruited to the lung of these subjects and secrete Th1-type cytokines upon beryllium recognition. The presence of circulating beryllium-specific CD4(+) T cells directly correlates with the severity of lymphocytic alveolitis. Since 1987, this biomarker of sensitization has enabled medical surveillance of beryllium-exposed workforces. Beryllium lymphocyte proliferation tests have been used to screen workers to detect sensitization, to characterize epidemiologically workplace risks for beryllium sensitization, and to evaluate the effectiveness of interventions intended to prevent sensitization. The most compelling real-world example of genetic testing for susceptibility to a workplace exposure involves those industries that process or fabricate beryllium. Under reasonable assumptions, the longitudinal positive predictive value of the HLA-DPB1-Glu69 marker of susceptibility to beryllium disease is 12%. Interpretive challenges further limit the utility of the test and may inadvertently suggest a false sense of safety among workers. Reduction in inhalation exposure to beryllium has not resulted in a concomitant reduction in the occurrence of beryllium sensitization or CBD, suggesting that continued prevalence may be due, in part, to unchecked skin exposure to beryllium-containing particles. (PMID: 17094767 , 16697706 , 16231190 ). |
---|
Structure | |
---|
Synonyms | Value | Source |
---|
Be(2+) | ChEBI | Be | HMDB | Beryllium atom | HMDB | Beryllium element | HMDB | Beryllium metallicum | HMDB | Beryllium-9 | HMDB | Glucinium | HMDB | Glucinum | HMDB |
|
---|
Chemical Formula | Be |
---|
Average Molecular Weight | 9.0122 |
---|
Monoisotopic Molecular Weight | 9.012182135 |
---|
IUPAC Name | beryllium(2+) ion |
---|
Traditional Name | beryllium(2+) ion |
---|
CAS Registry Number | 7440-41-7 |
---|
SMILES | [Be++] |
---|
InChI Identifier | InChI=1S/Be/q+2 |
---|
InChI Key | PWOSZCQLSAMRQW-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of inorganic compounds known as homogeneous alkaline earth metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkaline earth metal atom. |
---|
Kingdom | Inorganic compounds |
---|
Super Class | Homogeneous metal compounds |
---|
Class | Homogeneous alkaline earth metal compounds |
---|
Sub Class | Not Available |
---|
Direct Parent | Homogeneous alkaline earth metal compounds |
---|
Alternative Parents | Not Available |
---|
Substituents | - Homogeneous alkaline earth metal
|
---|
Molecular Framework | Not Available |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 1300 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Kovats Retention IndicesUnderivatized |
---|
Spectra |
---|
| |
---|
Biological Properties |
---|
Cellular Locations | Not Available |
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
|
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.0266 +/- 0.0155 uM | Adult (>18 years old) | Both | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.045 +/- 0.019 uM | Adult (>18 years old) | Not Specified | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.033 +/- 0.019 uM | Adult (>18 years old) | Both | Parkinson's disease | | details | Blood | Detected and Quantified | 0.0344 +/- 0.0189 uM | Elderly (>65 years old) | Both | Alzheimer's disease | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Alzheimer's disease |
---|
- Bocca B, Forte G, Petrucci F, Pino A, Marchione F, Bomboi G, Senofonte O, Giubilei F, Alimonti A: Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. Ann Ist Super Sanita. 2005;41(2):197-203. [PubMed:16244393 ]
| Parkinson's disease |
---|
- Forte G, Alimonti A, Pino A, Stanzione P, Brescianini S, Brusa L, Sancesario G, Violante N, Bocca B: Metals and oxidative stress in patients with Parkinson's disease. Ann Ist Super Sanita. 2005;41(2):189-95. [PubMed:16244392 ]
|
|
---|
Associated OMIM IDs | |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB022990 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 96830 |
---|
KEGG Compound ID | C16460 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Beryllium |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 107649 |
---|
PDB ID | 0BE |
---|
ChEBI ID | 30502 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Kreiss K, Day GA, Schuler CR: Beryllium: a modern industrial hazard. Annu Rev Public Health. 2007;28:259-77. [PubMed:17094767 ]
- Amicosante M, Fontenot AP: T cell recognition in chronic beryllium disease. Clin Immunol. 2006 Nov;121(2):134-43. Epub 2006 May 12. [PubMed:16697706 ]
- Day GA, Stefaniak AB, Weston A, Tinkle SS: Beryllium exposure: dermal and immunological considerations. Int Arch Occup Environ Health. 2006 Feb;79(2):161-4. Epub 2005 Oct 18. [PubMed:16231190 ]
|
---|